KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations (Q104795981)
Jump to navigation
Jump to search
scientific article published on 01 December 2020
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations |
scientific article published on 01 December 2020 |
Statements
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations (English)
Xiaoshan Zhang
Ran Zhang
Huiqin Chen
Li Wang
Chenghui Ren
Apar Pataer
Shuhong Wu
Qing H Meng
Min Jin Ha
Jeffrey Morris
Yuanxin Xi
Jing Wang
Jianhua Zhang
Don L Gibbons
John V Heymach
Funda Meric-Bernstam
John Minna
Jack A Roth
Bingliang Fang
1 December 2020